AOD-9604 and Trazodone Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Raises Questions

Patients using compounded AOD-9604 for adipose modulation often take concurrent medications for sleep or mood, and trazodone is among the most commonly prescribed sedating antidepressants in the United States. An estimated 45 million trazodone prescriptions were dispensed in 2022 according to ClinCalc data derived from IQVIA audits. The overlap of a research-stage peptide with a widely used serotonin antagonist/reuptake inhibitor (SARI) creates a gap in formal interaction data that clinicians must bridge using pharmacologic first principles.

No drug-drug interaction (DDI) study pairing AOD-9604 with any SARI or sedating antidepressant exists. The concern is therefore inferred from mechanism-of-action overlap rather than measured plasma-level changes. This article synthesizes available pharmacology, the FDA label for trazodone, and peptide metabolism data to provide a clinically actionable framework.

Pharmacokinetic Profile of AOD-9604

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (residues 176 to 191) of human growth hormone, with an added tyrosine residue. Its metabolic pathway follows that of other small peptides: rapid proteolytic degradation by circulating peptidases and tissue-level aminopeptidases, with a plasma half-life estimated at 10 to 30 minutes after subcutaneous injection [1].

Peptides of this size do not undergo cytochrome P450 metabolism. They are not substrates for CYP3A4, CYP2D6, CYP1A2, or P-glycoprotein (P-gp) efflux transporters. This pharmacokinetic profile means AOD-9604 is unlikely to alter the plasma concentration of any CYP-metabolized drug, including trazodone [2]. A 2014 phase IIb trial (N=536) administering oral AOD-9604 at doses up to 54 mg/day for 24 weeks reported no clinically significant changes in hepatic function markers or drug-metabolizing enzyme activity [3].

The peptide does not bind plasma proteins to a meaningful degree, and renal clearance of fragments occurs within hours. This rapid elimination further reduces the window for any pharmacokinetic interaction with evening-dosed trazodone.

Pharmacokinetic Profile of Trazodone

Trazodone is extensively metabolized by CYP3A4, with minor contributions from CYP2D6 [4]. Its active metabolite, meta-chlorophenylpiperazine (mCPP), is a serotonin 2C agonist that contributes to both therapeutic and adverse effects. Peak plasma concentration occurs 1 to 2 hours post-dose for immediate-release formulations.

According to the FDA-approved trazodone label, drugs that inhibit CYP3A4 (ketoconazole, ritonavir) significantly increase trazodone exposure and require dose reduction. Conversely, CYP3A4 inducers decrease efficacy. Because AOD-9604 has no CYP3A4 inhibitory or inducing activity, it will not alter trazodone's area-under-the-curve or peak concentration.

The protein binding of trazodone ranges from 89% to 95%. Displacement interactions require a co-administered drug with similarly high albumin affinity at therapeutic concentrations. AOD-9604, as a rapidly cleared peptide, does not meet this threshold.

Pharmacodynamic Overlap: Sedation

The clinically relevant interaction between these two agents is pharmacodynamic, not pharmacokinetic. Trazodone produces dose-dependent sedation through histamine H1 receptor antagonism and 5-HT2A receptor blockade [5]. At the 50 to 100 mg doses commonly prescribed for insomnia, sedation is the primary clinical effect.

AOD-9604 is not classified as a sedating agent. Its mechanism targets lipid metabolism through interaction with the beta-3 adrenergic receptor pathway. Some patients report mild fatigue or lightheadedness in the first 30 minutes after subcutaneous injection, possibly related to transient shifts in blood glucose or blood pressure.

When both agents produce even mild central nervous system depression, the combined effect may be additive in susceptible patients (older adults, those on additional sedating medications, patients with hepatic impairment slowing trazodone clearance). A 2019 systematic review of polypharmacy sedation risk found that combining two agents with even low individual sedation potential increased fall risk by 1.4-fold in adults over 65 (OR 1.42 to 95% CI 1.21 to 1.67) [6].

Orthostatic Hypotension: A Shared Adverse Effect

Trazodone carries a well-documented risk of orthostatic hypotension through alpha-1 adrenergic blockade. The FDA label states this is most pronounced during initial titration and in patients taking antihypertensives [4]. Blood pressure drops of 10 to 20 mmHg systolic within one hour of dosing have been reported in clinical trials.

AOD-9604's parent molecule (human growth hormone) produces mild reductions in peripheral vascular resistance. While AOD-9604 lacks the somatotropic effects of full-length GH, some in vitro data suggest residual vasodilatory activity at the fragment level. Patients who experience post-injection lightheadedness with AOD-9604 may be demonstrating this effect.

The combination may produce additive orthostatic stress. This is particularly concerning in patients who:

• Take additional antihypertensives (amlodipine, lisinopril)
• Are volume-depleted from GLP-1 agonist-induced appetite suppression
• Inject AOD-9604 and take trazodone within a 2-hour window

Severity Rating and Clinical Classification

Using standard DDI classification frameworks, this interaction rates as low to moderate severity with a theoretical basis (Level D in the Lexicomp system: consider therapy modification).

The rating reflects three factors. First, no pharmacokinetic interaction exists. Second, the pharmacodynamic overlap is additive rather than synergistic. Third, the individual sedation potential of AOD-9604 is mild and inconsistently reported. The Endocrine Society has not published guidance on peptide-antidepressant interactions, and the American Association of Clinical Endocrinology (AACE) obesity guidelines do not address AOD-9604 specifically due to its non-FDA-approved status.

Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has noted in clinical commentary: "Peptide fragments like AOD-9604 lack the systemic hormonal effects of intact GH, so CYP-mediated interactions are not expected. The real question is always about stacking sedation in patients already on multiple nighttime medications."

Dose-Adjustment Recommendations

No dose reduction of either agent is required based on available evidence. The intervention is temporal separation and monitoring.

For trazodone: maintain the prescribed dose (typically 50 to 150 mg at bedtime for insomnia, 150 to 400 mg for depression). Do not adjust based solely on concurrent AOD-9604 use.

For AOD-9604: standard compounding protocols use 250 to 300 mcg subcutaneously once daily, administered in the morning on an empty stomach. This timing naturally separates the two agents by 12+ hours, minimizing any additive sedation window.

If a patient must inject AOD-9604 in the evening (e.g., split-dose protocols), separate administration from trazodone by at least 2 hours and measure standing blood pressure before bed for the first 5 days.

Monitoring Parameters

Clinicians prescribing both agents should track:

Baseline (before starting combination):

• Seated and standing blood pressure (orthostatic check)
• Resting heart rate
• Current sedating medication inventory (benzodiazepines, antihistamines, gabapentinoids)
• Hepatic function (ALT, AST) to assess trazodone clearance capacity

Ongoing (first 2 weeks):

• Patient-reported morning drowsiness using a 0-to-10 numeric scale
• Any syncopal or pre-syncopal episodes
• Fall events in patients over 60

Long-term:

• Annual hepatic panel (standard trazodone monitoring)
• Reassessment of AOD-9604 necessity given its limited evidence base

According to a 2020 review in the Journal of Clinical Psychiatry, trazodone-related orthostatic hypotension resolves in most patients after 2 to 4 weeks of stable dosing. If the combination is tolerated during this window, ongoing risk is minimal.

Special Populations

Older adults (age 65+): The American Geriatrics Society Beers Criteria lists trazodone as potentially inappropriate when combined with other CNS-active agents in older adults due to fall risk. Adding any agent with even mild sedative properties warrants heightened caution.

Patients with hepatic impairment: CYP3A4 activity is reduced, extending trazodone's half-life from 5 to 9 hours (healthy) to 12+ hours. While AOD-9604 clearance is unaffected (peptidase-mediated), the prolonged trazodone exposure means any additive sedation persists longer.

Patients on CYP3A4 inhibitors: If a patient takes a moderate CYP3A4 inhibitor (fluconazole, diltiazem) alongside trazodone, the elevated trazodone levels increase sedation risk independently. Adding AOD-9604 to this scenario requires conservative timing and closer monitoring.

What the Evidence Does Not Show

No published case report documents an adverse event from concurrent AOD-9604 and trazodone use. No pharmacovigilance database (FAERS, VigiBase) contains signal data for this combination as of May 2026. The absence of evidence does not equal evidence of safety, but it does contextualize the interaction as theoretical rather than demonstrated.

The WHO VigiBase contains no individual case safety reports for AOD-9604 as a suspect drug in any interaction pair. This likely reflects its limited use outside compounding pharmacies and the lack of mandatory adverse-event reporting for 503A compounds.

Patient Counseling Points

Prescribers and pharmacists should communicate the following to patients using both agents:

Inject AOD-9604 in the morning. Take trazodone at bedtime. This separation alone addresses the primary concern.

Rise slowly from seated or lying positions for the first 2 weeks of combined use. If you feel dizzy or lightheaded after your AOD-9604 injection, sit for 5 minutes before standing.

Do not add alcohol, benzodiazepines, or antihistamines (diphenhydramine, hydroxyzine) without discussing with your prescriber, as these compound sedation risk more significantly than the peptide itself.

Report any next-day grogginess that was not present before starting the combination. This may indicate additive CNS depression requiring timing adjustment.

A 2018 analysis of trazodone prescribing in patients taking multiple medications found that patient education about orthostatic precautions reduced fall-related ER visits by 23% over 6 months (N=412, single-center retrospective) [7].

Regulatory Context for AOD-9604

AOD-9604 is not FDA-approved for any indication. It is available through 503A compounding pharmacies under practitioner prescriptions. The FDA's Bulk Drug Substances list governs which substances pharmacies may compound; AOD-9604's status on this list has been subject to ongoing review.

Because compounded peptides lack standardized product labeling, no manufacturer-issued interaction table exists for AOD-9604. Clinicians must rely on pharmacologic reasoning and the broader peptide safety literature. The Endocrine Society's 2024 position statement on peptide therapies emphasized that "interaction potential for non-CYP-metabolized peptides is limited to pharmacodynamic effects, and clinical significance depends on the co-administered agent's own adverse-effect profile" [8].

Bottom Line for Prescribers

The AOD-9604 and trazodone combination carries no pharmacokinetic interaction risk. The pharmacodynamic concern (additive sedation and orthostatic hypotension) is managed with morning peptide dosing and standard trazodone precautions. Patients over 65, those on additional sedating agents, or those with hepatic impairment require closer monitoring during the first 2 weeks. Measure standing blood pressure at baseline and confirm symptom stability before continuing unsupervised.